Navigation Links
Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
Date:2/22/2010

class="xn-money">$28,000 for the quarter ended December 31, 2008.

The net loss for the year ended December 31, 2009 was $220.2 million, or $2.04 per share, compared to $71.6 million, or $0.79 per share for the year ended December 31, 2008. This loss includes a non-cash fair value adjustment of $118.8 million or $1.10 per share associated with a change in the fair value of our warrants The size of this re-measurement is directly related to the price increase our common stock experienced this year.  Net loss in the fourth quarter of 2009 was $32.5 million or $0.28 per share, compared to a net loss of $8.8 million, or $0.09 per share, for the same period in 2008. Dendreon's total operating expenses for the year ended December 31, 2009 were $100.1 million compared to $70.6 million in 2008.

As of December 31, 2009, Dendreon had approximately $606 million in cash, cash equivalents, and short-term and long-term investments compared to $111 million as of December
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
2. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
5. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
7. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
8. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
11. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...   Unique Pizza and Subs Corporation ... a Delaware Corporation, is pleased to announce it ... Corporation ("Larasan"), a nature-based pharmaceutical company that produces and ... Larasan will work with Unique to help distribute ... vast distribution network throughout China ...
(Date:7/30/2014)... Germany , July 30, 2014  invendo medical ... computer-assisted ("robotic") colonoscopy system, today announced the appointment of ... device executive, as a new member of its supervisory ... respected global visionary in the medical device industry. In ... Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: GIVN), ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... Olympus , a precision technology leader in designing ... Products, among other core businesses, today announced the ... sinus spacing and hemostat products to its already ... foams and powders available in either plant-based or ...
... Services Corp. (RainTree Oncology), a privately-held provider of ... it has signed a distribution agreement with Metro ... of prescription and over-the-counter pharmaceuticals. The agreement marks ... and enables the Company to provide crucial oral ...
Cached Medicine Technology:Olympus Unveils New Dissolvable Post Sinus Surgery Products 2RT Oncology Services Signs Distribution Agreement with Metro Medical Supply, Inc. 2
(Date:7/30/2014)... Mozes HealthDay Reporter WEDNESDAY, ... help their preschooler shed excess pounds may want to team ... parents joined them in a supervised behavioral modification program gained ... traditional child-only program (an average difference of about four pounds ... 15 pounds over two years, according to the study. ...
(Date:7/30/2014)... 30, 2014 SF Cable, distributor of ... lowest prices on the internet with guaranteed customer satisfaction ... lengths and two colors. These lightning cords are MFI ... The high quality SF Cable Lightning to USB ... signal delivering faster charging and syncing. Compatible with the ...
(Date:7/30/2014)... 30, 2014 Imprivata ® ... management and secure communications solutions for the healthcare ... is the most widely selected single sign-on (SSO) ... Horizon electronic medical records (EMR) systems with a ... 11 percent in the last 12 months), according ...
(Date:7/30/2014)... (HealthDay News) -- Some obese people have a genetic ... in their brains when they see food, researchers report. ... triggers feelings of pleasure and gratification at the sight ... designed to prevent overeating, the scientists suggested. More ... typically caused by a combination of overeating, a ...
(Date:7/30/2014)... A new network of 25 regional stroke centers and ... StrokeNet) is working to change the way stroke ... of the last two decades, stroke remains a major ... disability for 795,000 Americans. The numbers are expected to ... , To accelerate the pace of progress, NIH StrokeNet ...
Breaking Medicine News(10 mins):Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2
... by a US biotechnology company could block the spread of ... human trial. // ,Human Immunodeficiency Virus (HIV) steadily ... fight off infections such as pneumonia, diarrhea, tumours and other ... die within three years of the first signs of the ...
... not to marry till he passes his Class 10 board exam, ... in the examination yet again! // ,Also known as Sheojiram, ... from here, has been taking the test for the last 37 ... vowed to marry only after getting through his secondary examinations. But ...
... while the chances of surviving a heart attack has improved ... ,The Canadian Institute for Health Information in its ... people suffering a new heart attack fell to 11.1 per ... in the case of strokes, 18.8 per cent of stroke ...
... Organisation (WHO) reaffirmed an additional case of the H5N1 avian ... from Tasikmalaya District, West Java Province who died on May ... in Indonesia have been fatal. The virus has taken a ... WHO report. Aproximately, 200 million birds too have perished.. ...
... Blair had lauded the initiation of a high profile, high-tech ... hospitals with the Britain’s 50 million patients//. Today however ... ,According to the first set grandiose plans, by 2005, ... immediately to surgeries. This would be followed by prescriptions that ...
... the intake of calcium and vitamin D supplements is apparently ... according to new results //from the Women's Health Initiative study. ... in decreasing the cancer risk. ,'We can't yet ... D individuals should take each day as supplements,' said Dr. ...
Cached Medicine News:Health News:New Revolutionary Drug Could Stop the Spread of HIV 2Health News:Survival Rates of Heart Attack Improving 2Health News:NHS Billions Spent on High Cost Computer Scheme 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: